Current developments in the diagnosis and treatment of giant cell arteritis

Link to article at PubMed

Front Med (Lausanne). 2022 Dec 13;9:1066503. doi: 10.3389/fmed.2022.1066503. eCollection 2022.


Giant cell arteritis is the most common vasculitis in adults above 50 years old. The disease is characterized by granulomatous inflammation of medium and large arteries, particularly the temporal artery, and is associated acutely with headache, claudication, and visual disturbances. Diagnosis of the disease is often complicated by its protean presentation and lack of consistently reliable testing. The utility of color doppler ultrasound at the point-of-care and FDG-PET in longitudinal evaluation remain under continued investigation. Novel techniques for risk assessment with Halo scoring and stratification through axillary vessel ultrasound are becoming commonplace. Moreover, the recent introduction of the biologic tocilizumab marks a paradigm shift toward using glucocorticoid-sparing strategies as the primary treatment modality. Notwithstanding these developments, patients continue to have substantial rates of relapse and biologic agents have their own side effect profile. Trials are underway to answer questions about optimal diagnostic modality, regiment choice, and duration.

PMID:36582285 | PMC:PMC9792614 | DOI:10.3389/fmed.2022.1066503

Leave a Reply

Your email address will not be published. Required fields are marked *